Please ensure Javascript is enabled for purposes of website accessibility

Why Inovio Stock Is Jumping Today

By Keith Speights – Aug 9, 2021 at 1:33PM

Key Points

  • Inovio's COVID-19 vaccine candidate, INO-4800, will be evaluated in two clinical trials in China as a booster to Sinovac's vaccine.
  • These studies are being sponsored by Inovio's partner, Advaccine, and by Sinovac.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Chinese regulators approved the initiation of two new clinical studies featuring Inovio's COVID-19 vaccine candidate, INO-4800.

What happened

Shares of Inovio Pharmaceuticals (INO 3.12%) were jumping 8.1% higher as of 12:53 p.m. EDT on Monday. The nice gain came after the company announced that it has received regulatory allowances to begin two clinical trials evaluating experimental COVID-19 vaccine INO-4800 in China.

So what

Inovio said that China's Center for Drug Evaluation of the National Medical Products Administration gave the green light for two clinical studies featuring INO-4800. Both studies will test Inovio's vaccine as a booster to Sinovac's CoronaVac.

A healthcare professional wearing a face shield giving a vaccine to a person.

Image source: Getty Images.

The company's partner, Advaccine Biopharmaceuticals Suzhou, is sponsoring these studies along with Sinovac. Inovio and Advaccine are already working together on a global phase 3 study evaluating INO-4800.

It's too soon to know how the latest studies in China will pan out. However, with the rise of the delta variant and concerns about the potential for other coronavirus variants to emerge, the testing of these vaccines with different mechanisms of action appears to be a prudent move.

Now what

Investors won't have to wait very long at all for more news that could serve as a potential catalyst for the biotech stock. Inovio reports its second-quarter results after the market close today. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

Inovio Pharmaceuticals Stock Quote
Inovio Pharmaceuticals
$1.98 (3.12%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.